First Horizon Corporation Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? First Horizon Corporation Common Stock trades at $22.63 (market cap $10.79B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: First Horizon Corporation Common Stock and Vaxcyte Inc. Common Stock are close in size by market cap, and First Horizon Corporation Common Stock pays a 2.99% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Horizon Corporation Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| FHN | PCVX | |
|---|---|---|
Market Cap | $10.79B | $10.51B |
Volume | 8,579,466 | 2,644,694 |
Sector | Financials | Health |
52-Week High | $26.23 | $73.82 |
52-Week Low | $19.94 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $14.10B | $9.14B |
Dividend Yield | 2.99% | — |
Signals from Pluang's Aura AI — not financial advice
First Horizon (FHN) trades at $22.77, down 1.26% on the day, with a neutral technical outlook. The stock shows strong fundamentals, including a P/E of 10.95 and net income margin of 30.87% for 2026, supported by three consecutive quarterly earnings beats. Recent news highlights executive recognitions and upcoming Q3 2026 earnings on October 15, 2026.
The outlook is positive given robust profitability, analyst consensus price target of $27.44 (20.5% upside), and no sell ratings. Risks include high debt-to-asset ratio of 1.81 and macroeconomic sensitivity. Earnings growth remains the key catalyst for further upside, with investor focus on Q3 results.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
First Horizon Corporation is the holding company for First Horizon Bank, a regional financial services provider operating roughly 460 branches across 11 states in southeastern US. It offers commercial, consumer, private banking, wealth management, and capital markets services.
Read more on FHN →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →